The proteasome is an intracellular enzyme complex that degrades ubiquitin-tagged proteins
and thereby regulates protein levels within the cell. Given this important role in maintaining …

The ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellular
proteins, including cell cycle regulatory proteins. Because these pathways are critical for the …

▪ Abstract The proteasome, a multicatalytic proteinase complex, is responsible for the
majority of intracellular protein degradation. Pharmacologic inhibitors of the proteasome …

With the approval by the US Food and Drug Administration of bortezomib for the treatment of
multiple myeloma and mantle cell lymphoma, the proteasome was clinically validated as a …

VELCADE®(bortezomib, Millennium Pharmaceuticals, Inc., Cambridge, MA, and Johnson &
Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ) is a first-in-class …

▪ Abstract Normal cellular functioning requires processing of proteins regulating cell cycle,
growth, and apoptosis. The ubiquitin-proteasome pathway (UBP) modulates intracellular …

Targeting intracellular protein turnover by inhibiting the ubiquitin–proteasome pathway as a
strategy for cancer therapy is a new addition to our chemotherapeutic armamentarium, and …

The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its
function is crucial to cellular homeostasis. First synthesized as probes of proteolytic …

The 26S proteasome is a large intracellular adenosine 5′-triphosphate–dependent
protease that identifies and degrades proteins tagged for destruction by the ubiquitin system …

Since 2003, the US Food and Drug Administration approval of bortezomib, a proteasome
inhibitor, has changed the management of hematologic malignancies and dramatically …